In late 2023, the FDA moved 19 widely-used research peptides from Category 1 — legally compoundable with a physician's prescription — to Category 2, which effectively banned them from licensed compounding pharmacies. The FDA cited immunogenicity concerns, manufacturing impurity risks, and insufficient large-scale human clinical data as the basis for the restriction. For researchers, clinicians, and individuals who had relied on compounding access, the reclassification created an abrupt and significant gap.
Then, on February 27, 2026, U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. announced that approximately 14 of those 19 peptides would be moved back to Category 1, restoring legal compounding access via licensed pharmacies with a physician's prescription. Kennedy framed the reversal as part of an ongoing scientific review and broader regulatory reform under his leadership at HHS.
Update: April 15, 2026 — The FDA Formal Action
Updated April 27, 2026: On April 15, 2026, the FDA formally removed 12 peptides from Category 2 of its Section 503A bulk drug substances list — making the February 27 HHS announcement official regulatory action. The FDA updated its document again on April 22, 2026. However, removal from Category 2 does not authorize compounding. The next required step is a Pharmacy Compounding Advisory Committee (PCAC) review, scheduled for July 23–24, 2026. Compounding pharmacies cannot legally produce these peptides until after that review and a subsequent FDA determination.
What Actually Changed — and What Did Not
The February 27, 2026 HHS Secretary announcement set a policy direction but was not itself a formal rule change. The April 15, 2026 FDA action was the formal step: the agency updated its official Section 503A bulk drug substances list, removing 12 specific peptides from Category 2 — the list of substances the FDA has determined raise significant safety concerns for compounding.
The 12 peptides removed from Category 2 as of April 15, 2026 are: BPC-157, LL-37, DiHexa, DSIP (Emideltide), Epitalon, GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500.
What did not change: compounding pharmacies are still not authorized to produce these peptides. Removal from Category 2 removes the explicit prohibition designation, but it does not place a substance on the 503A authorized bulks list. That requires a separate PCAC review and an FDA decision. Until that process concludes, the practical compounding status for patients and clinicians is unchanged.
The PCAC Review: July 23–24, 2026
The FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23–24, 2026. At that meeting, the committee will evaluate whether seven of the 12 removed peptides should be formally added to the Section 503A authorized bulk drug substances list. The first-batch peptides under review are: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax, and TB-500.
A second batch — covering the remaining removed peptides except GHK-Cu — is expected to be reviewed by early 2027. GHK-Cu has its own separate evaluation scheduled for February 2027.
The earliest a favorable PCAC recommendation could lead to legal compounding access for BPC-157, TB-500, and the other first-batch peptides is late Q3 2026, pending both a positive committee vote and follow-through from the FDA. Nothing is guaranteed.
Which Peptides Were Removed from Category 2
The 12 peptides removed from Category 2 on April 15, 2026, along with their current evidence classifications:
- BPC-157 — Evidence Level D/C. Body Protection Compound 157 has an extensive preclinical and animal research base, with data suggesting roles in tissue repair, gut health, and joint recovery. As of April 2026, no published human randomized controlled trial exists. Animal model findings are promising but cannot be extrapolated to confirmed human therapeutic benefit.
- TB-500 (Thymosin Beta-4) — Evidence Level D. Animal studies indicate potential roles in wound healing, cardiac tissue recovery, and angiogenesis. Human data is very limited. Research suggests meaningful effects in preclinical models, but human RCT evidence has not been established.
- Thymosin Alpha-1 — Evidence Level B. This is among the better-studied peptides on the list. Human clinical data exists for immune modulation in the context of hepatitis B, hepatitis C, and post-chemotherapy immune recovery. It is approved as a pharmaceutical agent in several countries outside the United States.
- CJC-1295 — Evidence Level C. A growth hormone-releasing hormone (GHRH) analogue with human data supporting growth hormone secretagogue effects. Long-term human studies are limited, and its regulatory status is research-only in the United States.
- Ipamorelin — Evidence Level C. A selective growth hormone secretagogue with some human data. Often combined with CJC-1295 in research protocols. Long-term safety and efficacy data in humans remains limited.
- AOD-9604 — Evidence Level C. A fragment of human growth hormone studied for fat metabolism. Some human trial data exists from earlier obesity research programs, though it was not approved as a pharmaceutical.
- Selank — Evidence Level C. A synthetic analogue of tuftsin with anxiolytic properties studied in Russian clinical research. Limited peer-reviewed English-language human data.
- Semax — Evidence Level C. A ACTH-derived peptide studied for cognitive and neuroprotective effects, with more established use in Russian medicine. Limited Western RCT data.
- KPV — Evidence Level D/C. A tripeptide with preclinical evidence for anti-inflammatory effects, particularly in gut research models. Human data is sparse.
- GHK-Cu — Evidence Level C. A copper peptide with research interest in skin biology and wound healing. Some human skin application data exists, though systemic use data is limited.
Note: the original February 2026 announcement anticipated approximately 14 peptides returning. The formal April 15 action covered 12. The gap between the two numbers reflects the FDA's final determination about which substances met the criteria for removal from Category 2 at this stage.
What Category 1 Status Actually Means
Returning to Category 1 does not mean these peptides are FDA-approved drugs. Several critical distinctions apply:
- Category 1 ≠ FDA approval. These remain unapproved compounds for off-label use, accessible only through licensed compounding pharmacies with a physician's prescription. They have not passed the FDA's drug approval process.
- Physician prescription required. Compounded peptides are not and will not be available over the counter. A licensed physician must evaluate and prescribe.
- Compounding pharmacy ≠ pharmaceutical-grade manufacturing. Quality standards at compounding pharmacies vary. Compounded preparations are not subject to the same manufacturing controls as FDA-approved drugs. Purity, potency, and sterility standards differ across facilities.
- WADA prohibited list is separate from FDA compounding status. For competitive athletes, the World Anti-Doping Agency's prohibited list governs what substances may be used. Many of the peptides expected to return to Category 1 — including BPC-157, TB-500, and growth hormone secretagogues — remain on the WADA prohibited list regardless of compounding legality in the United States.
What This Means for People Following This Space
The April 15 FDA action is a meaningful forward step, but legal compounding access has not been restored. For individuals interested in these peptides based on research interest or clinical consultation:
- The PCAC meeting on July 23–24, 2026 is the next gate. If the committee recommends inclusion on the 503A authorized bulks list and the FDA accepts that recommendation, legal compounding of BPC-157, TB-500, and the other first-batch peptides could resume by late Q3 2026.
- Until then, gray market is still the only route — with all the quality risks that entails. Purity, sterility, and concentration cannot be verified outside licensed compounding channels.
- A physician relationship matters. Consult a licensed physician who follows the regulatory process in this space. They will know when and whether legal compounding access actually resumes and can advise appropriately based on your individual situation.
PeptideWise will update this post after the July 23–24, 2026 PCAC meeting with outcomes for the first-batch peptides.
This article is for informational and educational purposes only. Nothing here constitutes medical advice, treatment recommendation, or encouragement to use any substance without appropriate medical supervision. Always consult a licensed healthcare provider.